Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis

Medical Mycology

Volumn 46, Issue 4, 2008, Pages 393-395

  Milefchik, Eric ^a   Leal, Mary Ann ^a   Haubrich, Richard ^b   Bozzette, Samuel A ^b   Tilles, Jeremiah G ^c   Leedom, John M ^a   Mccutchan, J Allen ^b   Larsen, Robert A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Cryptococcus neoformans; Drug treatment; Fluconazole; Flucytosine; Meningitis

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; WARFARIN;

ABDOMINAL PAIN; ADULT; AIDS RELATED COMPLEX; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; CEREBROSPINAL FLUID CULTURE; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FEMALE; GRANULOCYTOPENIA; HEARING; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA AND VOMITING; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; SKIN COLOR; SKIN PIGMENTATION; SWEATING; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT DURATION; VEIN THROMBOSIS; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FLUCONAZOLE; FLUCYTOSINE; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; NAUSEA; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VOMITING;

FILOBASIDIELLA NEOFORMANS;

EID: 42349101313     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780701851695     Document Type: Article

References (12)

1. Corbett, EL, Churchyard, GJ and Charalambos, S. (2002) Morbidity and mortality in South African gold miners: Impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis, 34, pp. 1251-1258.
2. Okongo, M., Morgan, D. and Mayanja, B. (1998) Causes of death in a rural, population-based human immunodeficiency virus type 1 natural history cohort in Uganda. Int J Epidemiol, 27, pp. 698-702.
3. Pitisuttithum, P., Tansuphasawadikul, S., Simpson, AJ, Howe, PA and White, NJ. (2001) A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. J Infect, 43, pp. 226-233.
4. Mwaba, P., Mwansa, J. and Chintu, C. (2001) Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J, 77, pp. 769-773.
5. Ford, BJ. (2000) AIDS and Africa. Biologist, 47, p. 224.
6. Gangaidzo, IT, Mielke, J. and Matenga, JA. (1999) Ethical considerations in the care of the patient with HIV/AIDS. Cent Afr J Med, 45, pp. 51-53.
7. Saag, MS, Graybill, RJ and Larsen, RA (2000) Practice guidelines for the management of cryptococcal disease. Clin Infect Dis, 30, pp. 710-718.
8. Larsen, RA, Bozzette, SA and Jones, BE (1994) Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis, 19, pp. 741-745.
9. Larsen, RA. (1990) Azoles and AIDS. J Infect Dis, 162, pp. 727-370.
10. Saag, MS, Powderly, WG and Cloud, GA (1992) Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med, 326, pp. 83-89.
11. Haubrich, RH, Haghighat, D., Bozzette, SA, Tilles, J. and McCutchan, JA. (1994) High-dose fluconazole for the treatment of cryptococcal disease in patients with human immunodeficiency virus infection. J Infect Dis, 170, pp. 238-242.
12. Hospenthal, DR and Bennett, JE. (1998) Flucytosine monotherapy for cryptococcosis. Clin Infect Dis, 27, pp. 260-264.